Infliximab

Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.

Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.

Biosimilar use among Medicare fee-for-service beneficiaries seems to depend most on practice setting and hospital ownership status, with few patient or physician characteristics linked to usage, according to data in JAMA Network Open.

Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.

Remicade and Entyvio were effective for the treatment of patients with checkpoint inhibitor-induced enterocolitis, according to the results of a meta-analysis.

Biologic therapies have been proven to significantly change treatment ability and improve the condition of patients with hidradenitis suppurativa, according to a presentation at the Interdisciplinary Autoimmune Summit.

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of nonadherence and discontinuation of the drug, according to study results.

The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.

There are many different treatments for inflammatory bowel disease, and choosing the right one for a patient with a new diagnosis can be a challenge.